Temozolomide SUN 20 mg hard capsules
Sponsors
Debiopharm International S.A., Bristol-Myers Squibb Services Unlimited Company, Nerviano Medical Sciences S.r.l., Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Institut De Recherches Internationales Servier IRIS
Conditions
Diffuse Midline GliomaGlioblastomaH3K27-alteredIDH1-mutant GliomaIDH2-mutant GliomaPan tumorRecurrent Glioblastoma
Phase 1
A phase 1/2 open-label study of Debio 0123 in combination with temozolomide in adult participants with recurrent or progressive glioblastoma and of Debio 0123 in combination with temozolomide and radiotherapy in adult participants with newly diagnosed glioblastoma
RecruitingCTIS2022-502156-31-00
Start: 2023-05-26Target: 55Updated: 2025-11-03
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
SuspendedCTIS2023-508318-41-00
Start: 2021-09-30Target: 36Updated: 2024-11-13
A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Active, not recruitingCTIS2024-513738-39-00
Start: 2025-03-18Target: 17Updated: 2025-12-18
FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial
Not yet recruitingCTIS2025-520814-78-00
Target: 20Updated: 2026-03-23
Phase 2
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax)
RecruitingCTIS2024-512493-98-00
Start: 2021-03-25Target: 28Updated: 2024-07-15